Gilead wagers $109M — cash — that this biotech can illuminate a drug discovery path pointed straight into the kidney
By any objective measure, Gilead has learned as much or more than virtually any other biopharma player about the liver. Now they’re going deeper, much deeper, into the kidney with the help of a Cambridge, MA-based biotech you may have forgotten about.
In a new discovery pact being unveiled Wednesday morning, the big biotech $GILD is committing $109 million — in cash — to start work with a biotech few in the global industry will likely recall off hand. Goldfinch Bio, a classic Third Rock startup crafted under the leadership of Abbie Celniker, has been building what it rather grandly calls the Kidney Genome Atlas to gather together a treasure trove of genetics and clinical data devoted entirely to the kidney. And they’ve added a biology platform of kidney cells and “organoids” to find drugs that can hit the precision targets they’ve identified.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
